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Summary
Alzheimer’s disease (AD) is the leading cause of dementia in the
elderly. Despite decades of study, effective treatments for AD are
lacking. Mitochondrial dysfunction has been closely linked to the
pathogenesis of AD, but the relationship between mitochondrial
pathology and neuronal damage is poorly understood. Sirtuins
(SIRT, silent mating type information regulation 2 homolog in
yeast) are NAD-dependent histone deacetylases involved in aging
and longevity. The objective of this study was to investigate the
relationship between SIRT3 and mitochondrial function and
neuronal activity in AD. SIRT3 mRNA and protein levels were
significantly decreased in AD cerebral cortex, and Ac-p53 K320
was significantly increased in AD mitochondria. SIRT3 prevented
p53-inducedmitochondrial dysfunction and neuronal damage in a
deacetylase activity-dependent manner. Notably, mitochondrially
targeted p53 (mito-p53) directly reduced mitochondria DNA-
encoded ND2 and ND4 gene expression resulting in increased
reactive oxygen species (ROS) and reduced mitochondrial oxygen
consumption. ND2 and ND4 gene expressions were significantly
decreased in patients with AD. p53-ChIP analysis verified the
presence of p53-binding elements in the human mitochondrial
genome and increased p53 occupancy of mitochondrial DNA in
AD. SIRT3 overexpression restored the expression of ND2 and ND4
and improved mitochondrial oxygen consumption by repressing
mito-p53 activity. Our results indicate that SIRT3 dysfunction
leads to p53-mediated mitochondrial and neuronal damage in AD.
Therapeutic modulation of SIRT3 activity may ameliorate mito-
chondrial pathology and neurodegeneration in AD.
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Introduction
Alzheimer’s disease (AD), the most common age-dependent neurode-
generative disease, is characterized by irreversible memory loss and
cognitive decline. Patients with AD may exhibit a range of behavioral and
psychological symptoms including mood changes. Degeneration of
subcortical cholinergic basal forebrain neurons may lead to the
dysfunction of gamma-amino butyric acid (GABA)ergic and glutamater-
gic neuronal systems, and degeneration of subcortical serotonergic and
aminergic nuclei may also contribute to AD symptoms (Coyle et al.,
1983; Canter et al., 2016). Accumulations of intracellular and extracel-
lular protein aggregates, that is neurofibrillary tangles containing
phosphorylated Tau protein and beta-amyloid plaques, directly con-
tribute to neuronal dysfunction and neurodegeneration and the devel-
opment of progressive development of dementia. Many therapeutic
approaches have targeted cholinergic restoration and beta-amyloid
removal, but unfortunately therapeutics directed at these targets have
had very limited success to date (Wolfe, 2002; Canter et al., 2016).
A growing body of evidence suggests that epigenetic modifications
contribute to AD pathogenesis (Lee & Ryu, 2010). Epigenetic changes
encompass an array of molecular modifications to both DNA and
chromatin, including transcription factors and cofactors. SIRTs (mam-
malian homolog of silent mating type information regulation 2 homolog
in yeast) are a family of epigenetic mediators that play various functions
in aging, chromatin integrity, metabolic regulation, and longevity (Kim
et al., 2007; Hirschey et al., 2010). Among sirtuins, SIRT1 has been
mostly widely studied and its level is changed in AD brains (Shi et al.,
2005; Someya et al., 2010; Kim et al., 2011).
SIRT3, the most abundant sirtuin in the brain, is localized to the
mitochondrial inner membrane and matrix and nucleus of neurons
(Onyango et al., 2002). It regulates mitochondrial activity by ROS in many
cell types and modulates CREB phosphorylation and fat metabolism (Shi
et al., 2005; Hirschey et al., 2010; Kim et al., 2010). Importantly, SIRT3
has an essential role in enhancing the mitochondrial antioxidant
glutathione,which could contribute to reduce aging inmammals (Someya
et al., 2010). Recently, it is reported that SIRT3 acts as a pro-survival factor
in neurons exposed to NMDA-induced excitotoxic injury (Kim et al.,
2011). SIRT3 expression is elevated in animals subjected to calorie
restriction, suggesting that SIRT3 may play a role in lifespan prolongation.
There are no differences in the frequency of SIRT3 gene methylation in
young vs. old human subjects or in patients with AD (Silva et al., 2008).
p53, a tumor suppressor protein and a transcription factor, translo-
cates to the inner mitochondrial matrix under normal condition and in
response to DNA damage (Marchenko et al., 2000; Mahyar-Roemer
et al., 2004). Mitochondrial p53 forms an inhibitory complex with Bcl2
and Bcl-xL resulting in the release of cytochrome c from mitochondria to
the cytosol and activation of caspases (Mihara et al., 2003). The
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translocation of p53 to mitochondria alters mitochondrial membrane
potential (Zhao et al., 2005). Interestingly, amyloid beta 42 activates p53
transcriptional activity and upregulates p53 expression in AD, suggesting
involvement of the p53 pathway in AD (Ohyagi et al., 2005). Notably,
p53 deficiency significantly decreases oxidative stress and activates
neuroprotective pathways (Barone et al., 2012; Fiorini et al., 2012).
Although many reports show an association between p53 and AD, little
is known about how p53 participates in neuronal mitochondrial activity
and mitochondria-encoded gene regulation in AD.
In spite of the abundance of SIRT3 and p53 in the neuronal mitochon-
dria, their function in the brain remains to be investigated. The mitochon-
dria-associated senescencedomainofp53can interactwithSIRT3 resulting
in growth arrest (Li et al., 2010). Because p53 is elevated in AD brain and
SIRT3 inducesmitochondrial ROSaccumulation inAD, ithasbeenproposed
that impaired molecular interactions between SIRT3 and p53 may lead to
mitochondrial dysfunction inAD(Hooperet al., 2007;Weiret al., 2012). In
this context, we discovered that that SIRT3 deacetylates p53, thereby
reducing p53 occupancy of mitochondrial DNA. In AD, SIRT3 levels are
reduced in ADmitochondria leading to increased Ac-p53 K320 levels and
increased p53 occupancy of mitochondrial DNA in AD. Through this
mechanism, SIRT3 and p53 contribute to dysregulation of mitochondrial
DNA-encoded gene expression and increased ROS accumulation, and
mitochondrial oxygen consumption in AD.
Results
SIRT3 mRNA and protein levels are decreased in AD
In order to identify the SIRT familymember (SIRT1 to 7) affected in patients
with AD, we first analyzed gene SIRT family expression profiles in the
frontal cortex of patientswith AD compared to normal subjects. Heatmap
analysis showed that SIRT3 expression is decreased to a greater degree
than other sirtuins in AD (Fig. 1A). SIRT3 was also found to have the
second highest level of relative expression among sirtuin family members
in brain. Based on these findings, we focused our study on SIRT3 changes
associated with AD. Next, to verify the altered SIRT3 gene expression, we
examined mRNA expression in frontal cortex of AD and normal subjects
using quantitative PCR analysis and found that SIRT3mRNA is significantly
decreased in patients with AD (n = 13) compared to normal subjects
(n = 13) (P < 0.05) (Fig. 1B). SIRT3 immunoreactivity was confined to
punctate structures within the cytosolic compartment of neurons in the
frontal cortex of normal subjects but was markedly reduced and
amorphous in patients with AD (Fig. 1C and S6). Western blot analysis
confirmed that SIRT3 protein levels are significantly decreased in AD
compared to normal controls (P < 0.05) (Fig. 1D). Thus, four different
methodologies confirmed that SIRT3 mRNA and protein levels are
apparently decreased in AD. As it has been shown that p53 expression
was increased in AD brain (Hooper et al., 2007) and SIRT3 alteration is
linked to ROS accumulation in AD (Weir et al., 2012), we examined the
relationship betweenSIRT3andp53protein levels inADcortex. p53protein
levels were significantly increased in both nuclear and mitochondrial
fractions of patients with AD while SIRT3 protein levels were significantly
decreased in the mitochondrial fraction (P < 0.05) (Fig. 1E,F). Linear
regression analysis showed an inverse correlation between SIRT3 and p53
protein levels in the mitochondria fraction of patients with AD (Fig. 1G).
SIRT3 physically interacts with p53
To examine molecular interactions between SIRT3 and p53, we used
several constructs including as Flag-p53 full-length, Flag-p53 N-terminal,
Fig. 1 Levels of SIRT3mRNA and protein are altered in AD. (A) A heat map showing that basal levels of SIRT gene expression are differentially regulated in AD cerebral cortex
compared tonormal subjects (Nor). Changes in gene expressions are the average of six samples fromeachgroupanddisplayed as higher (red) or lower (purple) color bars. (B) qRT–
PCRanalysis verified that SIRT3mRNA is decreased inADcortex (n = 13) compared tonormal subjects (n = 13).GAPDHwasused for normalizing SIRT3 expression. Thebar graph
data represents the mean  SEM (*P < 0.05). (C) SIRT3 immunoreactivity was decreased in AD frontal cortex. Scale bar: 30 lm. (D) Western blot analysis showed that SIRT3
protein levels are decreased in AD (n = 6) compared to controls (n = 6). Actin was used as the loading control. Densitometry analysis of SIRT3 protein represented that SIRT3
proteinwas significantly decreased in AD (*P < 0.05). (E)Western blot analysis shows that levels of p53were increased in nuclear andmitochondrial fractions of AD compared to
normal subjects, whereas levels of SIRT3 protein were decreased in the mitochondrial fractions in patients with AD. ACTB and TOM20 were used as loading controls of the
protein. (F) Densitometry analysis showed a significantly decreased SIRT3 but increased p53 protein levels in patients with AD. The bar graph data represent the mean  SEM
(*P < 0.05). (G) The regression analysis showed an inverse correlation between SIRT3 and p53 in the mitochondria fractions of patients with AD (n = 7, R2=0.8438, *P < 0.05).
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Flag-p53 mid-terminal, Flag-p53-DBD, and Flag C-terminal in in vitro
associations assays (Fig. 2A). The above p53 constructs were
cotransfected with GFP-SIRT3 in 293T cells, and SIRT3 protein was
immunoprecipitated by anti-GFP antibody. As shown in Fig. 3B, p53
mid-terminal region strongly interacted with SIRT3. To further confirm
the region or domain of SIRT3 interacting with p53, we performed a GST
pull-down assay using wild-type GST-SIRT3 and three GST-SIRT3
truncated fragments (Fig. 2C). Our results showed that the N-terminal
of SIRT3 protein preferentially interacts with p53 (Fig. 2D).
SIRT3 prevents mitochondrially targeted p53 (mito-p53)-
induced neuronal damage and mitochondrial dysfunction by
deacetylating p53 at K320
To define the effects of SIRT3 on p53-dependent neuronal activity, we
cotransfected mito-p53 with WT SIRT3 or DSIRT3 in DIV7 primary cortical
neurons and determined neuronal DNA damage and mitochondrial
function (Onyango et al., 2002; Shi et al., 2005). As expected, ectopic
expression of mito-p53 induced significant (around 80%) neuronal DNA
damage (indicating DNA fragmentation by DAPI staining) compared to
control vector (DsRed)-transfected neurons (around 20%) (Fig. 3A,B).
WT SIRT3 overexpression significantly decreased mito-p53-induced DNA
damage to around 40%, whereas mutant DSirt3 did not significantly
prevent mito-p53-induced DNA damage (around 70%) (P < 0.05) (Fig.
3A,B). We assayed the cytochrome c levels using immunofluorescence
staining as a measure of mitochondrial dysfunction (Mihara et al., 2003).
Mito-p53-transfected neurons showed two times lower intensity than
control neurons (control vector-transfected cells). WT SIRT3 overexpres-
sion recovered more than 80% of the cytochrome c intensity to a level
similar to control neurons while mutant DSIRT3 did not restore
cytochrome c intensity (P < 0.05) (Fig. 3A,C). Together, our data
indicate that SIRT3 plays a protective role against mito-p53-induced
DNA damage and mitochondrial dysfunction in primary neurons.
Several studies have shown the apoptotic role of p53 acetylation at
the K320 residue (Sakaguchi et al., 1998; Terui et al., 2003; Roy et al.,
2005; Brandl et al., 2012). In order to determine whether SIRT3
modulates p53 acetylation, we performed Western blot analysis after
cotransfection of SIRT3 and p53 constructs in SH-SY5Y cells. SIRT3
overexpression reduced p53 acetylation at K320, but not at other lysine
residues including K373, K381, and K382 in SH-SY5Y cells (Fig. 4A, left
panel). To further verify the role of SIRT3 in p53 acetylation at K320, we
cotransfected CBP/p300 which is generally known to induce p53
acetylation (Ito et al., 2001; Koh et al., 2014) and ran Western blot
analysis. As shown in Fig. 4A (right panel), while CBP robustly increased
p53 acetylation at K320, SIRT3 effectively reduced p53 acetylation at
K320 by CBP. To further validate whether p53 acetylation at K320 is
associated with neuronal damage, primary neurons were transfected
with an acetylation site mutant p53 (K320R) and an acetylation mimetic
mutant p53 (K320Q) and stained with DAPI and MitoTracker (Fig. 4B,C).
MitoTracker intensity is a well-established surrogate for mitochondrial
Fig. 2 SIRT3 physically interacts with p53. (A) Schematic illustrating full-length WT p53 and p53 deletion constructs. (B) SIRT3 interacts with the several domains of
p53. Flag-p53 full-length, Flag-p53 N-terminal, Flag-p53 mid-terminal, Flag-p53 C-terminal, and Flag-p53 DBD constructs were cotransfected with GFP-SIRT3 in 293T
cells, and equal amounts of protein from cell lysates were immunoprecipitated with anti-FLAG M2 antibody followed by immunoblotting with anti-FLAG M2 antibody to
detect p53 and with anti-GFP antibody to detect SIRT3, respectively. A representative experiment is shown. (C) Schematic showing full-length GST-SIRT3 and truncated
forms of GST-SIRT3. (D) GST-SIRT3 pull-down assay confirmed that SIRT3 is physically associated with p53. In vitro GST-SIRT3 pull-down was performed with cell lysates
extracted from SH-SY5Y cells with p53 overexpression. GST fusion proteins were visualized by Coomassie blue staining (bottom panel).
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Fig. 3 SIRT3 prevents p53-induced
mitochondrial and DNA damage in primary
cortical neurons. (A) Photomicrographs
show that SIRT3 prevents mito-p53-
induced neuronal damage. DIV7 primary
mouse cortical neurons were transfected
with pDsRed control vector or pDsRed mito-
p53 with SIRT3 or DSIRT3 for 36 h. Primary
neurons were treated with 0.1% saponin (5
min on ice) to release cytosolic content
prior to fixation and were subjected to
immunostaining for cytochrome c staining
and nuclear counterstaining with DAPI.
Images were captured by confocal
microscopy. Representative images of four
separate experiments are shown. Scale bar
(white): 10 lm. (B) SIRT3 prevents mito-
p53-induced neuronal DNA damage. The
DNA fragmentation was analyzed from
transfected neurons and the bar graphs
represent the mean  SEM (n = 4;
*P < 0.05). (C) SIRT3 prevents mito-p53-
induced mitochondrial damage. The bar
graphs represent relative endogenous
cytochrome c (FITC) intensity that is
quantified using Nikon NIS-Elements AR
software. Error bars represent S.E.M (n = 4;
**P < 0.01, ***P < 0.001).
Fig. 4 SIRT3 regulates deacetylation of p53 at K320 and p53-induced neuronal damage. (A) SIRT3 deacetylates p53 at K320. H1299 p53 KO cells were cotransfected p53
with HA-CBP, or with GFP-SIRT3 for 24 h, respectively. ACTB was used as loading control. (B) Schematic structures show constructs of wild-type p53, K320R mutant, and
K320Q mutant. (C) p53 induces neuronal damage in an acetylation of K320-dependent pathway. DIV7 primary mouse cortical neurons were cotransfected EGFP with
vector, p53, K320R, K320Q, p53 and SIRT3, and K320Q and SIRT3 for 36 h. Neurons were stained with MitoTracker Red CMXRos for 30 min prior to fixation and were
subjected in DAPI staining. Scale bar (white): 10 lm. (D) SIRT3 modulates mitochondrial activity through the deacetylation of p53 K320. The graph data represent the
mean  SEM (n = 4; *P < 0.05, ***P < 0.001). (E) SIRT3 modulates p53-induced DNA damage through the deacetylation of p53 K320. The DNA fragmentation was
analyzed from transfected neurons and the bar graphs represent the mean  SEM (n = 4; *P < 0.05, **P < 0.01). (F) Western blot analysis shows that levels of acetylated
p53 at K320 were increased in both nucleus and mitochondria fractions of AD compared to control, whereas SIRT3 was decreased in mitochondria fractions of AD. ACTB
and COX4 were used as the loading control. (G) Immunoreactivity of acetylated p53 at K320 was increased in the nucleus and the mitochondria of AD. Arrows (white)
indicate cytoplasmic and mitochondrial localization of acetylated p53K320 signals. Scale bar (white): 20 lm. (H) Electron micrograph showed that immunogold-labeled
particles of acetylated p53 at K320 are found in the mitochondria of cortical neurons and its level is increased in patient with AD compared to normal (Nor) subject.
Arrowheads (red) indicate cytoplasmic and mitochondrial localization of acetylated p53K320 signals. M, mitochondria; N, nucleus. Scale bars: 500 nm.
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membrane potential (MMP) (Favret & Lynn, 2010). Our data showed that
MitoTracker intensity was significantly decreased in both WT p53-
transfected and mutant p53 K320Q-transfected neurons compared to
control or mutant p53 K320R-transfected neurons (P < 0.05) (Fig. 4B–
D). Notably, WT SIRT3 recovered WT p53- or mutant p53K320Q-induced
mitochondrial membrane permeability transition (MMPT) (P < 0.05)
(Fig. 4C,D). In addition, WT SIRT3 prevented WT p53- or mutant
p53K320Q-induced neuronal DNA fragmentation (P < 0.05) (Fig. 4C,E).
To confirm whether acetylated p53K320 level is altered in AD, we
measured acetylated p53 at K320 using Western blot analysis,
immunohistochemistry, and immunogold labeling and TEM analysis in
AD and control frontal cortex. The level of acetylated p53 at K320 was
significantly increased in patients with AD (n = 6) compared to normal
subjects (n = 6) (Fig. 4F,G). The gold particles for acetylated p53K320
were found in the mitochondria and p53K320-positive gold particles
were increased in patients with AD compared to normal subjects
(Fig. 4H). Accordingly, our results demonstrate that both the WT p53
and acetylated p53 at K320 are altered by AD pathology.
SIRT3 prevents mito-p53-induced cell death and
mitochondrial dysfunction
To gain more insight into the role of SIRT3 in mito-p53-induced cell death
and mitochondrial dysfunction, tetracycline-inducible mito-p53 SH-SY5Y
cell lines were developed. Figure 5A depicts the strategy we used to
generate inducible mito-p53 and SIRT3 cell lines. Doxycycline (DOXY) was
Fig. 5 SIRT3 prevents mito-p53-induced mitochondrial dysfunction and neuronal death. (A) A scheme shows SIRT3/mito-p53 double expression cell model. (B) SIRT3
improved mito-p53-induced cell viability. SIRT3/mito-p53 double or mito-p53 single inducible cell lines were treated with or without 2 lg mL1 DOXY for 0, 12, 18, 24, 30,
and 42 h, respectively. Cell viability was analyzed by MTT assay. (C) Ectopic expression of SIRT3 prevented mito-p53-induced apoptosis. Apoptotic cells were analyzed by
flow cytometry after Annexin V/ PI staining in mito-p53-inducible cell with or without SIRT3 overexpression. The bar graph data (bottom panel) represents the mean  SEM
(n = 3; *P < 0.05, ***P < 0.001). (D) SIRT3 improved mito-p53-induced mitochondrial membrane potential (Ψ) loss. Mitochondrial membrane potential was detected by
flow cytometry after JC-1 staining in mito-p53-inducible cell with or without SIRT3 overexpression. The bar graph data represent the mean  SEM (n = 3; *P < 0.05,
**P < 0.01). (E) Ectopic expression of SIRT3 reduced mito-p53-induced ROS production. Reactive oxygen species (ROS) were analyzed by flow cytometry after DCF staining in
mito-p53-inducible cell with or without SIRT3 overexpression. The bar graph data represent the mean  SEM (n = 3; *P < 0.05).
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applied for the indicated time periods, and the cell viability was measured.
When mito-p53 was induced by DOXY treatment, cell viability was
markedly and progressively decreased over time. In contrast, induction of
SIRT3 togetherwithmito-p53 significantly prevented cell death (P < 0.05)
(Figs 5B and S1A,B, Supporting information). Previous reports have shown
that SIRT3 plays a protective role in diverse stress-induced cell death
(Hagen et al., 1995; Kim et al., 2007; Hirschey et al., 2010). To determine
whether SIRT3 prevents mito-p53-induced toxicity, mito-p53 cells were
transfected with a control vector, WT SIRT3, or mutant DSIRT3 and cells
were then stained with Annexin V and propidium iodide (PI). WT SIRT3
overexpression, but not mutantDSIRT3, significantly decreasedmito-p53-
induced early and late apoptosis (P < 0.05) (Figs 5C and S1C). Our data
strongly indicate that WT SIRT3 rescues mito-p53-dependent late apop-
tosis. Next, in order to detect MMP changes, we stained mito-p53 cells in
the presence ofWT SIRT3 ormutantDSIRT3with JC-1. JC-1monomerwas
significantly increased in DOXY-treated mito-p53 cells (R1 area of flow
cytometry scatter plot). WT SIRT3 overexpression significantly decreased
the formation of JC-1 monomer in mito-p53 cells (P < 0.05) (Fig. 5D).
MutantDSIRT3 did not rescueMMP levels reduced bymito-p53 (Fig. S1D).
Normal SH-SY5Y cells were transfected withWT p53, mutant p53K320Q,
ormutant p53K320R in thepresenceandabsenceofWTSIRT3 followedby
Annexin V/PI staining. We found that WT SIRT3 rescues WT p53- and
mutant p53K320Q-induced cell death (P < 0.05) (Fig. S2). We then
performed DCF-DA staining and flow cytometry analysis to determine
whether oxidative stress pathway is associated with mito-p53-dependent
mitochondrial dysfunction. ROS accumulation was robustly increased in
DOXY-treated mito-p53 cells (Fig. 5E). WT SIRT3 overexpression signifi-
cantly decreased ROS accumulation in DOXY-treated mito-p53 cells
(P < 0.05) (Fig. 5E). Our results demonstrate that SIRT3 plays a protective
role against mito-p53-induced ROS-mediated mitochondrial dysfunction
and cell death (Fig. S8).
SIRT3 regulates p53-dependent mitochondrial genome
expression and modulates mitochondrial ROS level and
oxygen consumption
To further investigate whether mitochondrially targeted p53 directly
regulates mitochondrial genome expression and SIRT3 modulates p53-
dependent mitochondrial gene expression, we performed a series of
experiments including ChIP and qRT–PCR. As shown in Fig. 6A,
induction of mito-p53 by DOXY treatment significantly decreased
expression of ND2, ND4, and 12S rRNA genes at 12 h (P < 0.05). Other
mitochondria genome-encoded genes were partially affected by mito-
p53 induction (Fig. S3). Consistent with the result of DOXY-inducible
mito-p53 cells, both ND2 and ND4 mRNA levels were significantly
decreased in the frontal cortex of patients with AD compared to normal
subjects while there was no significant change in the mRNA level of 12S
rRNA (P < 0.05) (Fig. 6B and S7). Next, we applied p53-chromatin
immunoprecipitation (ChIP) and qPCR assays to identify whether p53
occupies mitochondrial DNA (mtDNA) and whether its occupancy is
altered in AD. Interestingly, p53 occupancy of mtDNA was markedly
increased in patients with AD compared to normal subjects (P < 0.05)
(Fig. 6C). Additionally, DNA sequencing of p53-ChIP qPCR product
verified that p53 preferentially occupies the ND2 and 12S rRNA
mitochondrial genes (Fig. S4). To test whether putative mitochondrial
consensus p53-binding element (mito-p53 BE) is transcriptionally regu-
lated by p53 (Heyne et al., 2004), we generated mito-p53 BE-driven
reporter construct using pGL3E luciferase vector (Fig. S5A). p53 induced
mito-p53 BE-driven reporter activity in a dose-dependent manner,
indicating that p53 can directly participate in transcriptional regulation of
the mitochondrial genome (Fig. S5B,C). WT SIRT3 decreased mito-p53
BE-driven reporter activity (Fig. S5D). These data suggest that SIRT3
modulates p53-dependent mitochondrial transcriptional activity. Even
though the reporter assay was designed for testing participation of p53
in mitochondrial genome transcription via mito-p53 BEs, mito-p53 BE-
driven reporter activity did not exactly correlate with net levels of
mitochondrial gene expression in cell lines and human AD brains.
WT SIRT3 rescued ND2 and ND4 mRNA levels in mito-p53 cells,
indicating that WT SIRT3 modulates mitochondrial ND2 and ND4
expression that is negatively regulated by mito-p53. (P < 0.05) (Fig. 6D).
Because mito-p53 may affect intracellular ROS levels via repression of
mitochondria-encoded Complex I genes such as ND2 and ND4, we
measured alterations in ROS level and oxygen consumption rate (OCR) in
DOXY-treated mito-p53 cells. Mito-p53 induction increased ROS levels
and reduced oxygen consumption capacity in a time-dependent manner
(P < 0.05) (Fig. 6E–G). WT SIRT3 decreased ROS levels and increased
OCR in DOXY-treated mito-p53 cells (P < 0.05) (Fig. 6E,H,I). Mutant
DSIRT3, however, did not reduce ROS levels or increase OCR in DOXY-
treated mito-p53 cells (Fig. 6G,H). These data suggest that mito-p53-
induced Complex I-dependent mitochondrial dysfunction causes ROS
accumulation by reducing ND2 and ND4 mRNA levels. SIRT3 restores
mito-p53-reduced basal mitochondrial oxygen consumption and mito-
chondrial oxidative capacity by rescuing mito-p53-reduced ND2 and ND4
mRNA levels and reducing mito-p53-changed ROS levels. To further
verify whether ND2 and ND4 mediate a neuroprotective effect in
response to SIRT3 and mito-p53, loss of function of ND2 and ND4 was
analyzed using siRNAs as shown in Fig. S9 (Table S3). Knock down of
ND2 and ND4 by siRNAs significantly decreased SIRT3-dependent cell
viability in SH-SY5Y cells. On the other hand, knock down of ND2 and
ND4 by siRNAs increased levels of cleaved caspase-3 in SH-SY5Y cells.
Discussion
Alterations of SIRT3 and mitochondrial p53 levels are
associated with AD pathology
Mitochondrial dysfunction has been closely linked to the pathogenesis of
AD, but the relationship between mitochondrial pathology and neuronal
damage is poorly understood (Bonilla et al., 1999; Swerdlow, 2012). In
the present study, we found that reduced mitochondrial SIRT3 is
associated with altered mitochondrial respiratory activity and neuronal
damage in AD. SIRT3 mRNA and mitochondrial SIRT3 protein levels were
significantly decreased, and mitochondrial p53 protein was significantly
increased in AD cortex. Furthermore, levels of mitochondrial SIRT3 are
inversely correlated with mitochondrial p53 in AD cortex, suggesting
that mitochondrial SIRT3 and p53 alterations may contribute to AD
pathogenesis. A significant downregulation of SIRT3 among SIRT family
members indicates that SIRT3 expression may be regulated in a gene
context-dependent manner in the context of AD. We propose that the
disparity between SIRT3 mRNA and protein levels in AD may be due to a
differential sensitivity of assay methods between qPCR vs. Western blot.
Otherwise, it is possible that differential alteration of transcription vs.
translation may contribute to the different levels of SIRT3 mRNA and
protein through a yet unknown pathway.
SIRT3 deacetylates p53 at K320 and prevents p53
neurotoxicity
The immunoprecipitation data showed that SIRT3 interacts with middle
regions of the p53 protein (amino acids 44-360). GST pull-down
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experiments confirmed that the N-terminal of SIRT3 (amino acids 1-97)
interacts with several p53 domains including both activation and DNA
binding domains. Our data are consistent with a previous report that
SIRT3 interacts with the mitochondria-associated senescence domain
(MASD) between amino acids 64 and 209 of p53 (Li et al., 2010).
Interestingly, it has shown that SIRT3 rescues p53-induced growth arrest
and senescence and Bcl2-associated athanogene 2 (BAG-2), a chaperone
protein, inhibited the rescue function of SIRT3 (Li et al., 2010). The
coordinated interaction between p53, SIRT3, and BAG-2 is closely linked
to the regulation of cell fate through a transcription-independent
pathway (Li et al., 2010).
Most notably, for the first time, we identified that SIRT3 specifically
reduces the level of Ac-p53 K320 and further blocks CBP-induced p53
acetylation at K320. These data suggest a bona fide role for SIRT3 as a
deacetylase that catalyzes the deacetylation of p53 at K320. To further
determine how Ac-p53 K320 affects neuronal activity, we examined the
function of mutant p53 K320R (a mimic of non-acetyl lysine) and K320Q
(a mimic of acetyl lysine) in primary neurons. As expected, the
p53 K320Q mutant induced mitochondrial dysfunction and cell death,
while the p53 K320R mutant did not. In addition, SIRT3 overexpression
nullified the pathological changes induced by WT p53 and p53 K320Q,
supporting our hypothesis that SIRT3 prevents p53-induced mitochon-
drial dysfunction and neuronal cell death. Previous studies support our
finding that p53 acetylation at the K320 residue is linked to cell damage
(Sakaguchi et al., 1998; Terui et al., 2003; Roy et al., 2005; Brandl
et al., 2012). Importantly, we found that Ac-p53 K320 levels are
significantly increased in the mitochondria of AD in conjunction with
reduced SIRT3 levels. In this context, failure of deacetylation of
Fig. 6 SIRT3 involves in mito-p53-dependent mitochondrial genome expression, mitochondrial ROS level, and oxygen consumption. (A) Mito-p53 repressed mitochondria-
encoded gene expression. The bard graph data represent the mean  SEM (n = 3; *P < 0.05). (B) The mRNA levels of ND2 and ND4 were significantly reduced in the cortex
of patients with AD compared to normal subjects. The graph data represent the mean  SEM (n = 6; *P < 0.05). (C) Quantitative ChIP analysis confirmed that p53
occupancy to mitochondrial DNA was elevated in the cortex of patients with AD compared to normal subjects (n = 6; *P < 0.05). (D) SIRT3 rescued expression of
mitochondria-encoded genes that are repressed by mito-p53. The bar graph data represent the mean  SEM (n = 3; *P < 0.05, **P < 0.01). (E) SIRT3 reduced mito-p53-
induced oxidative stress (ROS accumulation). Cells were subjected to DCF-DA staining followed by flow cytometry. The line graph data represent the mean  SEM (n = 5;
**P < 0.01). (F) Mito-p53 reduced mitochondrial oxygen consumption and respiratory function. Cells were applied to oligomycin, FCCP, antimycin, and rotenone followed
by oxygen consumption rate (OCR) analysis. (G) The OCR level was significantly reduced by mito-p53. The bar graphs were originated from (E) panel (n = 5, **P < 0.01,
***P < 0.005). (H) SIRT3 rescues mitochondrial oxygen consumption and respiratory function affected by mito-p53. (I) SIRT3 significantly restores the OCR level decreased by
mito-p53. The bar graphs were originated from (H) panel (n = 5, *P < 0.05, **P < 0.01). (J) A flowchart illustrates that, in a condition of AD pathology, a reduction in SIRT3
levels leads to an increase in acetylated p53 (K320) levels in the mitochondria and impairs mito-p53-dependent mitochondrial genome expression, resulting in elevations of
ROS accumulation and neuronal damage.
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mitochondrial Ac-p53 at K320 due to the decreased SIRT3 activity may
initiate cascades of mitochondria-dependent neuronal damage pro-
cesses in AD.
SIRT3 modulates p53-dependent mitochondrial genome
expression and mitochondrial activity
We determined that SIRT3 modulates mito-p53-dependent mitochon-
drial gene expression and mitochondrial respiratory function. As a result,
SIRT3 prevented mito-p53-induced mitochondrial dysfunction and neu-
ronal damage in both primary neurons and SH-SY5Y cells. Mitochondrial
ND2 and ND4 genes encode core subunits of the mitochondrial
membrane respiratory chain NADH dehydrogenase (Complex I) (Mathie-
sen & Hagerhall, 2002; Brandt, 2006). Complex I functions in the
transfer of electrons from NADH to the respiratory chain (Hayashi &
Stuchebrukhov, 2010). Previous studies have shown that mRNA levels of
mitochondrial genome-encoded Complex I (ND4), COX I, COX II, and
COX III genes are significantly decreased in AD temporal cortex
(Chandrasekaran et al., 1996; Fukuyama et al., 1996). Our results
suggest that reduced SIRT3 in AD causes mito-p53-dependent repression
of ND2, ND4, and 12s rRNA gene expression.
The association between p53 and mtDNA had been hypothesized
because of its localization in the mitochondrial inner matrix (Fukuyama
et al., 1996). We identified that p53 binds to potential consensus binding
elements in the human mitochondrial genome and p53 binding to
mtDNA was elevated in AD. It seems likely that the higher p53 occupancy
to mtDNA is related to repression of ND2 and ND4 gene expression in
AD. In this context, SIRT3 may modulate p53 binding to mtDNA by
deacetylating p53 at K320 and thereby coordinate mitochondrial gene
expression. We previously reported that cAMP response element binding
protein (CREB) is localized to neuronal mitochondria and specifically
binds to CREB response elements in the mitochondrial genome that
regulate mitochondrial-encoded Complex I gene expression (Lee et al.,
2005; Ryu et al., 2005). In the current study, we provide another layer of
mechanism that increased mito-p53 level leads to ROS accumulation and
reduces the rate of mitochondrial oxygen consumption. In contrast, SIRT3
prevents ROS accumulation and restores mitochondrial oxygen con-
sumption by modulating mito-p53 activity. Collectively, our data indicate
that the deregulation of SIRT3 impairs mitochondrial gene expression via
mitochondrial p53 activation in AD. Previous studies have shown that
mitochondrial ROS are generated both via mitochondrial respiration and
by oxygen-independent processes under physiologic conditions in a cell
type-specific and metabolic rate-dependent manner (Kushnareva et al.,
2002; Barja, 2007). Based on previous findings, we expect that the
increased ROS levels and concomitant reduced oxygen consumption
capacity caused by mito-p53 may contribute to neuronal dysfunction.
How ROS generation is regulated independent of oxygen consumption
warrants further investigator in the future.
A novel role of p53 in the mitochondria of AD
Since their initial finding of mitochondrial p53 in 2000 (Marchenko
et al., 2000), Moll and colleagues have performed pioneering studies,
showing that p53 is specifically targeted to mitochondria and plays
transcription-independent pro-apoptotic functions (Mihara et al., 2003;
Erster & Moll, 2004; Moll et al., 2005). p53 directly interacts with
multidomain proteins of the Bcl-2 family at the mitochondrial outer
membrane and induces mitochondrial outer membrane permeabiliza-
tion, which is a prominent apoptotic checkpoint (Mihara et al., 2003;
Tomita et al., 2006; Follis et al., 2014). Several stresses such as hypoxia
and ischemia induce translocation of p53 protein to mitochondria
(Sansome et al., 2001; Erster & Moll, 2004; Vaseva et al., 2012).
Mitochondrially targeted p53 leads to cell death in solid tumor models
(Palacios et al., 2008). Intriguingly, p53 physically interacts with
cyclophilin D (CypD) and the p53-CypD complex results in mitochondrial
permeability transition pore opening and mediates cell death caused by
ischemic injury. Cyclosporine A pretreatment or reduction of p53
proteins prevents formation of the p53-CypD complex in an ischemic
injury mouse model (Vaseva et al., 2012). In the current study, we found
that SIRT3 rescues mito-p53-induced cytochrome c release in primary
neurons. Release of cytochrome c from mitochondria is a well-known
upstream event to trigger caspase-3-dependent neural cell damage.
Teng et al. (2004) have shown that spinal cord injury (SCI) increases
mitochondrial cytochrome c release and minocycline treatment provides
neuroprotective effect by reducing cytochrome c release in SCI. These
data suggest that therapeutic regulation of mitochondrial function may
be an effective approach to treat neurotrauma. Whether this therapeutic
approach modulates SIRT3 and mito-p53-dependent pathway remains
to be investigated.
The novel roles of p53 in the mitochondria have been well
documented (Park et al., 2016). p53 interacts with mtDNA-associated
proteins such as CHCHD4, OGG1, Parkin, POLG, and TFAM (Achanta &
Huang, 2004; Achanta et al., 2005; and Wong et al., 2009; Hoshino
et al., 2013; Zhuang et al., 2013). In conjunction with partner
molecules, p53 is involved in modulating mtDNA replication and
transcription, maintaining mtDNA stability, and repairing mtDNA.
Bergeaud et al. recently showed that mitochondrial p53 interacts with
oligomycin sensitivity-conferring protein, a component of F1F0-ATP
synthase complex, and promotes the assembly of F1F0-ATP synthase
complex (Bergeaud et al., 2013). These reports show that p53 is directly
involved in mitochondrial respiratory function through its interaction
with mitochondrial matrix proteins. Our novel findings show that
elevation of mitochondrial p53 activity contributes to the pathogenesis
of AD through its role as a mitochondrial transcription factor. The
mitochondrial p53 activity was modulated by SIRT3 in neurons. Based on
our current study, further work will be necessary to define what signals
and other factors are associated with p53-mediated mitochondrial
transcription normally and in neurodegenerative conditions such of AD.
In summary, we found reduced SIRT3 levels in neuronal mitochondria
in AD that inversely correlate with increased levels of mitochondrial p53.
In addition, levels of Ac-p53 K320 were elevated in neuronal mitochon-
dria of AD. Decreased SIRT3 levels lead to mitochondrial dysfunction via
p53-mediated reduction of mitochondria genome-encoded ND2 and
ND4 expression in AD. Consequently, altered activity of SIRT3 and p53
impaired mitochondrial oxygen consumption and enhanced neuronal
damage in AD. Taken together, alterations of SIRT3 and mitochondrial
p53 may be a marker for mitochondrial dysfunction in AD and
therapeutic modulation of SIRT3 activity may be a useful strategy to
ameliorate mitochondrial pathology in AD.
Experimental procedures
Cell culture
Mouse cortical primary neurons from P0 pups were cultured in
Neurobasal medium supplemented with 1XB-27 supplement and 1X
L-glutamine (Invitrogen, CA, USA) in a humidified atmosphere of 5%
CO2 at 37°C. 293T cells, SH-SY5Y cells, and doxycycline (DOXY)-
inducible mitochondrially targeting p53 (mito-p53) cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; Thermo Scientific,
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Waltham, MA, USA) supplemented with 10% fetal bovine serum) and
1% penicillin/streptomycin (P/S) in a humidified atmosphere of 5% CO2
at 37°C.
Chemicals and antibodies
Anti-SIRT3, anti-COX4, anti-FLAG M2, and anti-ACTB antibodies were
obtained from Sigma (St. Louis, MO, USA). Rabbit anti-HA and mouse
anti-p53 (DO-1) antibodies were purchased from Santa Cruz (Dallas, TX,
USA). Rabbit anti-acetyl-p53 K373/382 and rabbit anti-acetyl-p53 K320
antibodies were purchased from Millipore (Billerica, MA, USA). Rabbit
acetyl-p53 K381 antibody was purchased from Abcam (Cambridge, MA,
USA). Mouse anti-cytochrome c antibody (Clone: 6H2.B4) was pur-
chased from BD Pharmingen (Franklin Lakes, NJ, USA). Secondary
antibodies including goat anti-mouse IgG and goat anti-rabbit IgG were
purchased from Jackson ImmunoResearch (West Grove, PA, USA).
Human brain samples
Neuropathological processing of control and AD human brain samples
was performed using procedures previously established by the Boston
University Alzheimer’s Disease Center (BUADC). All brains were donated
with consent of the next of kin after death. Institutional review board
approval was obtained through the BUADC. The study was performed in
accordance with institutional regulatory guidelines and principles of
human subject protection in the Declaration of Helsinki. Detailed
information of brain tissues is described in Table S1.
Quantitative real-time PCR (qPCR)
Total RNA was isolated from brain tissues using a commercial extraction
system (Qiagen). 1 lg total RNA has been used for cDNA preparation with
iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) according to the
manufacturer’s protocols. cDNA from each sample was amplified by real-
time PCR using iQ SYBR Green Supermix (Bio-Rad). RNA quantities were
normalizedusingGAPDHmRNAasa reference. PCRcycling conditionswere
asfollows:denaturationfor3 minat95°C;then40cyclesofamplificationfor
15 s at 95°C, 15 s at 60°C, 20 s at 70°C; followedby 30 s at 72°C. Formelt
curve, data collection has been used 33 cycles, 6 s each, with the tempera-
tureincreasedfrom60°Cto92°C(increasesetpointtemperatureaftercycle2
by 1°C). The PCRprimer for SIRT3was as follows: forward, 5’-CGGCTCTAC
ACGCAGAACATC-3’ and reverse, 5’-CAGCGGCTCCCCAAAGAACAC-3’;
the PCR primer for ND2was as follows: forward, 5’- GAGTAGATTAGGCGT
AGGTA-3’ and reverse, 5’-CGGCCTGCTTCTTCTCA-3’;ND4: forward,5’-C
TAGGCCATATGTGTTGGA-3’ and reverse, 5’- GTATATCGCCTCACACCT
CA-3’; and 12s rRNA: forward, 5’- CGGTATATAGGCTGAGCA-3’ and
reverse, 5’- GGAACAAGCATCAAGCA-3’ (Table S2).
Immunogold labeling and transmission electron microscopy
(TEM)
Immunogold labeling and TEM were performed with some modification
as previously described (Lee et al., 2005; Ryu et al., 2005). The tissues
were fixed with 2.5% glutaraldehyde dissolved in 0.1M cacodylate
buffer overnight at 4°C and with 2% osmium tetroxide for 1 h. The cells
were dehydrated with ethanol series, infiltrated with Spurr’s resin series,
and polymerized at 60°C for 8 h. The embedded cell was cut with a
diamond knife on ultramicrotome (Ultracut S, Leica). The sections were
mounted directly on 150-mesh nickel grids. The sections were treated
with 3% H2O2 for 30 min and incubated with the AURION Blocking
Agent for 30 min. Then, the sections were incubated with the anti-
acetylated-p53 (Ac-p53)-rabbit IgG. The sections were then rinsed with
0.2%-BSA-C (AURION, the Netherlands) in PBS and incubated with
30-nm gold-conjugated anti-rabbit antibody for 1 h. After washing
with 0.1% BSA-C in PBS, the sections were treated with 0.2%
glutaraldehyde and washed with distilled water. The sections were
stained with 2% uranyl acetate solution for 10 min. The grids were
examined with Tecnai F20 (FEI, the Netherlands) at 200 kV. Negative
control was incubated with secondary antibody only while primary
antibody was omitted.
Statistical analysis
The data are presented as the mean  SEM. Data analysis was
performed by Student’s t-test using StatView 4 (Abacus Concepts,
Berkeley, CA, USA). Differences were considered statistically significant
when P < 0.05.
Other detailedmethods are included in Supporting Information (Data S1).
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Fig. S1 SIRT3 prevents mito-p53-induced cell death.
Fig. S2 SIRT3 prevents both WT p53- and mutant p53 K320Q-induced cell
death.
Fig. S3Mitochondrial genome-encoded transcripts are regulated bymito-p53.
Fig. S4 Human mitochondrial p53-binding elements were determined by p53-
ChIP followed by DNA sequencing.
Fig. S5 Sirt3 modulates p53-dependent transcriptional activity of mitochon-
drial p53-binding element (Mito-p53BE)-driven reporter.
Fig. S6 SIRT3 is mainly expressed in neuronal cell types.
Fig. S7 (A) Doxycycline (DOXY) does not affect mitochondrial genome-
encoded gene expression in normal SH-SY5Y cells.
Fig. S8. (A) Western blot shows that SIRT3 reduces caspase-3 activation
induced by p53. Arrow (red) indicates the position of cleaved caspase-3. (B)
SIRT3 significantly reduces the level of cleaved caspase-3 induced by p53.
Fig. S9 Knock down of ND2 and ND4 decreases SIRT3-dependent neuropro-
tective effect against p53.
Table S1 Information on human normal and AD brain samples.
Table S2Primer sequences for qPCR analysis ofmitochondrial genes (F, forward;
R, reverse).
Table S3A list of siRNA sequences for humanmitochondria (MT)-encodedND2
and ND4 genes.
Data S1 Experimental Procedures.
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